Watch: This Is Why Biden’s $2 Trillion Infrastructure Plan Will Fail
In the United States, we have a problem that’s so BIG and obvious that even Elon Musk can’t see it. Our highways are broken, our streets are clogged with traffic,...
COVAXX, a Long Island biotech company developing a multitope synthetic peptide-based vaccine to fight COVID-19, has announced a global logistics partnership with Maersk, one of the world’s largest shipping and integrated logistics providers. The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities. Financial terms of the agreement are not disclosed.
The investigational vaccine “UB-612” is designed to mimic natural biology. The technology platform has been successful in commercializing blood diagnostics as well as safe and effective vaccines for infectious disease in animal health and has been tested in numerous clinical trials for other indications to date.
Maersk will help fulfill this mission by overseeing all logistics activities to ensure efficient transportation to developing countries. The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain.
COVAXX is planning to manufacture 100 million doses of UB-612 during early 2021, and a billion doses by the end of 2021. The design of the vaccine components will allow for the use of existing cold-chain storage and distribution channels, as the COVAXX vaccine does not require additional infrastructure such as -80?C freezers or liquid nitrogen tanks to store materials at extreme temperatures.
“The COVAXX vaccine is unique in that it can be stored in the fridge you have at home, moved in the same trucks that deliver groceries and administered anywhere you can get a flu shot.” – Lou Reese Co-Chief Executive Officer of COVAXX.
“Efficient and safe delivery of COVID-19 vaccines around the world is the most urgent logistics challenge we face today,” said Rob Townley, Head of Special Project Logistics at Maersk. “Our specialized logistics expertise and the global infrastructure of Maersk make this a perfect match.”
Join the 67,723 members that receive our newsletter.
Have a news tip? Let us know.